Comparison of drug permeabilities and BCS classification: Three lipid-component PAMPA system method versus Caco-2 monolayers

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 238-241

  Teksin, Zeynep S ^a,b   Seo, Paul R ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Biopharmaceutics classification system; Caco 2; Membrane transport; PAMPA; Permeability

Indexed keywords

ACICLOVIR; AMFEBUTAMONE; ATENOLOL; CARBAMAZEPINE; CHLORPHENIRAMINE; COUMARIN; DISOPYRAMIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; INULIN; KETOPROFEN; MANNITOL; METOPROLOL; NAPROXEN; PIROXICAM; PROPRANOLOL; RANITIDINE; THEOPHYLLINE; VERAPAMIL;

ARTICLE; ARTIFICIAL MEMBRANE; CELL STRAIN CACO 2; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG PENETRATION; DRUG SCREENING; MEMBRANE TRANSPORT; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CACO-2 CELLS; CELL LINE; CELL MEMBRANE PERMEABILITY; DOGS; HUMANS; MEMBRANES, ARTIFICIAL; METOPROLOL; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; REFERENCE STANDARDS;

EID: 77950647738     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9176-2     Document Type: Article

References (37)

1. Teksin ZS, Hom K, Balakrishnan A, Polli JE. Apparent ion pairmediated transport of metoprolol across a three lipid component PAMPA system. J Control Rel. 2006;116:50-57 (Pubitemid 44792301)
2. Kerns EH, Li D, Petusky S, Farris M, Ley R, Jupp P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci. 2004;93(6):1440-1453 (Pubitemid 38725018)
3. Avdeef A, Strafford M, Block E, Balogh MP, Chambliss W, Khan I. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in piper methysticum Forst. Eur J Pharm Sci. 2001;14:271-280 (Pubitemid 33001619)
4. Wohnsland F, Faller B. Permeability pH profile and highthroughput alkane/water log P artificial membranes. J Med Chem. 2001;44:923-930
5. Seo PR, Teksin ZS, Kao JPY, Polli JE. Lipid composition effect on permeability across PAMPA. Eur J Pharm Sci. 2006;29:259-268
6. Sugano K, Nabuchi Y, Machida M, Asoh Y. Permeation characteristics of a hydrophilic basic compound across a biomimetic artificial membrane. Int J Pharm. 2004;275:271-278 (Pubitemid 38481539)
7. Palm K, Luthman K, Ros J, Grasjo J, Artursson P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. J Pharmacol Exp Ther. 1999;291:435-443 (Pubitemid 29503509)
8. Hwang K, Martin NE, Jiang L, Zhu C. Permeation prediction of M100240 using the parallel artificial membrane permeability assay. J Pharm Sci. 2003;6(3):315-320 (Pubitemid 38097544)
9. Polli JE, Ginski MJ. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharm Res. 1998;15:47-52.
10. Tolle-Sander S, Grill A, Joshi H, Kapil R, Persiani S, Polli JE. Characterization of dexloxiglumide in vitro biopharmaceutic properties and active transport. J Pharm Sci. 2003;92:1968-1980 (Pubitemid 37175628)
11. Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, Tsinman O, et al. PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci. 2004;21:429-441 (Pubitemid 38283916)
12. Fujikawa M, Ano R, Nakao K, Shimizu R, Akamatsu M. Relationships between structure and high-throughput screening permeability of diverse drugs with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg Med Chem. 2005;13:4721-4732 (Pubitemid 40848350)
13. Avdeef A, Artursson P, Neuhoff S, Lazorova L, Grasjö J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci. 2005;24:333-349 (Pubitemid 40283516)
14. Masungi C, Mensch J, Van Dijck A, Borremans C, Willems B, Mackie C, et al. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie. 2008;63:194-199 (Pubitemid 351449929)
15. Koljonen M, Rousu K, Cierny J, Kaukonen A, Hirvonen J. Transport evaluation of salicylic acid and structurally related compounds across Caco-2 cell monolayers and artificial PAMPA membranes. Eur J Pharm Biopharm. 2008;70:531-538
16. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci. 2006;27:354-362 (Pubitemid 43143261)
17. Lipoid E 80 product brochure. LipoidGmbH, Ludwigshafen. 2006.
18. Guidance for Industry, Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000, CDER/FDA. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070246.pdf (accessed 1/12/2010).
19. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci. 2004;93:1945-1956 (Pubitemid 39045477)
20. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(Suppl B):29-37. (Pubitemid 14238677)
21. Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res. 2000;17(2):135-140
22. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2)cells. Biochem Biophys Res Com. 1991;175(3):880-885
23. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28-33. (Pubitemid 29037364)
24. Zakeri-Milania P, Valizadeha H, Tajerzadehc H, Azarmia Y, Islambolchilara Z, Barzegara S et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007;10:368-379 (Pubitemid 350065177)
25. Dollery Sir C. Therapeutic drugs. Livingstone: Churchill; 1991.
26. Ritschel WA, Brady ME, Tan HS. First-pass effect of coumarin in man. Int J Clin Pharmacol Biopharm. 1979;17(3):99-103.
27. Lima JJ, Haughey DB, Leier CV. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14Cdisopyramide. J Pharm Biopharm. 1984;12(3):289-313. (Pubitemid 14023154)
28. Hardman JG, Limbird LE. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.
29. Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/ pharmacodynamic review (Part I). Clin Pharmacokin. 1990;18(5):381-408. (Pubitemid 20134544)
30. Zhu C, Jiang L, Chen TM, Hwang KK. A comparative study of artificial membrane permeability assay for high-throughput profiling of drug absorption potential. Eur J Med Chem. 2002;37(5):399-407. (Pubitemid 34465549)
31. Roberfroid MB. Concepts in functional foods: The case of inulin and oligofructose. J Nutrition. 1999;129(7):1398-1401
32. Li C, Wainhaus S, Uss A, Cheng K. High-throughput screening using Caco-2 Cell and PAMPA systems. In: Ehrhardt C, Kim KJ, editors. In drug absorption studies in situ, in vitro and in silico models. Springer US; 2008. p. 418-429.
33. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res. 1997;14(6):763-766 (Pubitemid 27281671)
34. Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15 (9):1490-1494 (Pubitemid 28427942)
35. Grant SM, Langtry HD, Brogden RN. Ranitidine: An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989;37(6):801-870
36. Hendeles L, Weinberger M, Bigley L. Absolute oral bioavailability of oral theophylline. Am J Hosp Pharm. 1977;34:525-527
37. Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006;8(1):E1-13.